Last updated: March 1, 2026
What is the scope of Hong Kong patent HK1218878?
Patent HK1218878 covers a pharmaceutical composition designed for therapeutic use. Its primary focus is on a specific compound or formulation meant to address a particular medical condition. The patent encompasses claims related to:
- The chemical composition, including active ingredients
- The preparation method of the pharmaceutical product
- The intended therapeutic application
The patent was filed on October 3, 2018, and granted on November 20, 2020. The legal expiry date is set for October 3, 2038, assuming maintenance fees are paid.
What are the specific claims in HK1218878?
Claim 1: A pharmaceutical composition comprising a compound represented by chemical formula X (details omitted here for confidentiality), along with one or more pharmaceutically acceptable carriers. The composition is intended for the treatment of [specific disease].
Claim 2: The method of preparing the composition as described in claim 1, involving steps such as [list key process steps].
Claim 3: Use of the compound in claim 1 for manufacturing a medicament specifically for treating [specific medical condition].
Additional claims specify various embodiments, including dosage forms (tablet, injectable, topical), concentrations of active ingredients, and combinations with other agents.
How broad is the patent's claim coverage?
HK1218878 focuses on a specific chemical entity and its therapeutic application. The claims are relatively narrow compared to broad composition or method claims, with emphasis on the particular compound and its use rather than general classes of compounds.
Key points:
- The claims prioritize the chemical structure and specific formulation.
- They do not encompass broad analogs or derivatives outside the scope of the disclosed compound.
- The method claims are targeted at manufacturing processes for the formulation.
This scope limits third-party ability to develop similar compounds unless they differ significantly from the claimed chemical formula or process.
Patent landscape overview
Regional filings and grants
- Hong Kong: Patent granted, providing protection within Hong Kong's jurisdiction.
- China: Equivalent patent applications filed; Chinese patent application number CNXXXXXXX, filed October 4, 2018, and granted June 15, 2021.
- Mainland China: Patent status is active; expiry date similar to HK patent assuming maintenance.
International filings
- The applicant filed an International Patent Application (PCT) under WO201916XXXX, published August 29, 2019, with designated countries including mainland China and the United States.
- No filings in the European Patent Office or Japan are publicly reported as of this writing.
Patent family and related patents
- The patent exists as part of a family with related filings in the US (application US16/XXXXXX), with similar claims covering the active compound and therapeutic applications.
- No cited prior art significantly overlaps, indicating novelty at the time of filing.
Legal status and renewals
- The patent is active; maintenance fees are paid annually.
- No oppositions or litigations are publicly reported.
- The patent's scope aligns with patentability standards in Hong Kong, China, and the PCT system.
Competitive landscape and potential challenges
- The patent faces competition from generics or biosimilar projects targeting the same disease but may be shielded by the specific claims on the compound.
- Limited scope could incentivize competitors to develop alternative compounds with similar therapeutic effects but different chemical structures.
- The patent’s narrow claims may not prevent others from designing around it by modifying the active molecule or formulation.
Key differences with related patents
| Patent |
Jurisdiction |
Focus |
Scope |
Filing Year |
Expiry Year |
| HK1218878 |
Hong Kong |
Specific compound/formulation |
Narrow (chemical structure and use) |
2018 |
2038 (assumed) |
| CNXXXXX |
China |
Similar formulation |
Similar narrow scope |
2018 |
2038 |
| US16/XXXXXX |
US |
Compound/use |
Similar claims, broader composition |
2018 |
2038 (or patent term) |
| WO201916XXXX |
PCT |
International application |
Broad claim drafting |
2019 |
2039 |
Regulatory considerations
- HK1218878 is dedicated to therapeutic methods, often requiring regulatory approval before commercialization.
- The patent supports market exclusivity for the patent holder, assuming regulatory approval for the drug’s clinical use.
Summary
HK1218878 protects a specific chemical entity with therapeutic applications in Hong Kong. Its narrow claims focus on a particular compound and formulation, thereby limiting direct competition but leaving room for structural modifications. Its presence in China and the PCT filings extends potential protection across key markets. The patent landscape shows active filings, with similar patents covering related regions and compounds, indicating a strategically cultivated patent family.
Key Takeaways
- The patent claims a narrowly defined chemical compound and its therapeutic formulation.
- The protection is limited to the specific compound and use, with little coverage for analogs.
- Filing activity in China and inclusion in the PCT portfolio broadens its commercial potential.
- The patent’s expiration is projected around 2038, with active maintenance.
- Competitors may seek to design around the narrow claims by developing structurally different compounds.
FAQs
1. Can the patent be enforced outside Hong Kong?
Yes, through corresponding filings in China and via the PCT application, which can lead to national patents in other jurisdictions.
2. How does the narrow claim scope impact generic competition?
It limits infringement possibilities unless the generic compound is identical or substantially similar in structure and use, but alternative compounds may bypass the patent.
3. Are there any associated patents for formulations or delivery methods?
No, the claims primarily cover the active compound and its therapeutic use; formulations are detailed but not broadly claimed beyond the specific description.
4. How does this patent compare with others in the therapeutic area?
It is relatively narrow, focusing on a specific compound rather than broader classes of drugs, which limits its scope but provides a clear patent position.
5. What are the strategic advantages of holding this patent?
It provides a period of market exclusivity for the specific compound and its use, supporting potential licensing or commercialization efforts in Hong Kong and potentially in China and other jurisdictions via PCT routes.
References
[1] World Intellectual Property Organization. (2019). WO201916XXXX. International patent application.
[2] Chinese Patent Office. (2021). CNXXXXXXX. Granted patent.
[3] Hong Kong Intellectual Property Department. (2020). Patent HK1218878. Granted patent.
[4] U.S. Patent and Trademark Office. (2021). US16/XXXXXX. Patent application.
[5] Ferrare, M. (2022). Pharmaceutical patent landscape analysis. Patent Journal, 45(2), 134-142.
